postpartum depression

Postpartum depression: A role for psychedelics?

mycolabadmin

Postpartum depression affects many new mothers and involves feelings of disconnection from themselves and their babies. This review suggests that psilocybin, the active compound in psychedelic mushrooms, might help by promoting reconnection and acceptance. The authors examine safety data suggesting psilocybin could potentially be used safely in postpartum women if appropriate precautions are taken, such as temporarily stopping breastfeeding after treatment.

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

mycolabadmin

Depression is a serious mental health condition affecting over 300 million people worldwide, with many patients not responding well to standard antidepressants. This review examines both traditional antidepressants like SSRIs and exciting new treatments including ketamine and psilocybin, as well as brain stimulation techniques. The key finding is that different treatments work through similar mechanisms—all ultimately enhancing brain cell connections and reducing inflammation—suggesting that combining different approaches might work better than single therapies.

4-Hydroxy-N,N-diisopropyltryptammonium hydrofumarate: Crystal Structure of a Synthetic Psychedelic

mycolabadmin

Scientists have determined the three-dimensional crystal structure of 4-HO-DiPT, a synthetic compound related to psilocin found in magic mushrooms. This is the first crystal structure of this specific compound and provides important structural information for understanding how it works. A related version of this compound is currently being tested in clinical trials for treating postpartum depression and other mood disorders.

Psilocybin During the Postpartum Period Induces Long-Lasting Adverse Effects in Both Mothers and Offspring

mycolabadmin

A new study shows that psilocybin, a psychedelic compound being tested for postpartum depression, may actually cause harm during the breastfeeding period. While the drug helped non-pregnant mice feel less anxious, it made postpartum mothers more anxious and worsened their caregiving behaviors. Even more concerning, baby mice exposed to psilocybin through breast milk developed mood and social problems as adults, suggesting potential lasting risks for human infants.

New and emerging pharmacologic treatments for MDD

mycolabadmin

Major depressive disorder affects millions worldwide and current antidepressants often don’t work well or take weeks to be effective. Researchers have developed exciting new treatments that work through different brain mechanisms and show promise for rapid symptom relief. These include nasal spray ketamine (approved 2019), oral medications like zuranolone (approved 2023), and investigational treatments including psilocybin, which show benefits especially for treatment-resistant cases. While many show great promise, more research is needed on long-term safety and how to make them widely available.

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring

mycolabadmin

Researchers tested whether psilocybin could help postpartum depression in mice, but found it actually made things worse for both mothers and their babies. While psilocybin normally reduces depression and anxiety, it had the opposite effect during the postpartum period, making mothers more anxious and disrupting their care of pups. Babies exposed to psilocybin through breastfeeding or direct exposure developed anhedonia (inability to feel pleasure) as adults. These findings suggest that the postpartum period may be a particularly vulnerable time for psychedelic use, and more research is needed before considering these drugs for postpartum depression treatment.

Developmental Neurotoxicity Screen of Psychedelics and Other Drugs of Abuse in Larval Zebrafish (Danio rerio)

mycolabadmin

Researchers tested 13 mind-altering drugs on developing zebrafish to see if they cause birth defects or behavioral problems. They found that psychedelics like psilocybin and ketamine were relatively safe for developing organisms, but traditional drugs of abuse like cocaine and methamphetamine caused significant behavioral changes without obvious physical defects. The study provides important safety information for these compounds, especially for pregnant or nursing individuals considering their use for therapeutic purposes.

Disease: postpartum depression